The Role of Extracellular Heat Shock Proteins in Cardiovascular Diseases

Patnaik, Soumya; Nathan, Sriram; Kar, Biswajit; Gregorič, Igor D.; Li, Yi-Ping

doi:10.3390/biomedicines11061557

Cited by 7 publications

(5 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, extracellular HSP70 has been detected in the medium of antigen-presenting cells (APCs), inducing T-cell activation. Extracellular HSP60 has been identified in the plasma of some individuals, but its source remains unknown [41]. Extracellular HSPs such as HSP27, αBC, and HSP20 are secreted into the extracellular medium via non-classical pathways and play important roles in cell-to-cell communication, cell signaling, immunity, stress tolerance, inflammation, and anti-apoptotic activities [42].…”

Section: Grp170mentioning

confidence: 99%

The Interplay between Heat Shock Proteins and Cancer Pathogenesis: A Novel Strategy for Cancer Therapeutics

Somu,

Mohanty,

Basavegowda

et al. 2024

Cancers

View full text Add to dashboard Cite

Heat shock proteins (HSPs) are developmentally conserved families of protein found in both prokaryotic and eukaryotic organisms. HSPs are engaged in a diverse range of physiological processes, including molecular chaperone activity to assist the initial protein folding or promote the unfolding and refolding of misfolded intermediates to acquire the normal or native conformation and its translocation and prevent protein aggregation as well as in immunity, apoptosis, and autophagy. These molecular chaperonins are classified into various families according to their molecular size or weight, encompassing small HSPs (e.g., HSP10 and HSP27), HSP40, HSP60, HSP70, HSP90, and the category of large HSPs that include HSP100 and ClpB proteins. The overexpression of HSPs is induced to counteract cell stress at elevated levels in a variety of solid tumors, including anticancer chemotherapy, and is closely related to a worse prognosis and therapeutic resistance to cancer cells. HSPs are also involved in anti-apoptotic properties and are associated with processes of cancer progression and development, such as metastasis, invasion, and cell proliferation. This review outlines the previously mentioned HSPs and their significant involvement in diverse mechanisms of tumor advancement and metastasis, as well as their contribution to identifying potential targets for therapeutic interventions.

show abstract

Section: Grp170mentioning

confidence: 99%

The Interplay between Heat Shock Proteins and Cancer Pathogenesis: A Novel Strategy for Cancer Therapeutics

Somu,

Mohanty,

Basavegowda

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Also, HSP70 is being released from necrotic or apoptotic cells [59,60]. Some fraction of HSP70 molecules are integrated into cell membrane, which ensures a quick reaction of HSP70 if necessary; also, these molecules can act as targets for autoimmunity [24,60]. In extracellular space, HSP70 stimulates the innate and adaptive immune system and works as an active mediator of the inflammatory process [60-62].…”

Section: н а д о п о м о г у л і к а р ю -п р а к т и к уmentioning

confidence: 99%

“…However, a large number of scientists have paid much attention to study of HSP70 role in hypertension [15,[17][18][19][20][21][22][23] and related cardiovascular diseases [24], including atherosclerosis [25,26], heart failure and ischemic heart disease [27][28][29][30], vascular disease [31].…”

mentioning

confidence: 99%

What is in common between preeclampsia, HPS70 and medieval headwear? Part II. Serum HSP70 in superimposed preeclampsia: original study

Popel,

Govsieiev

2024

RHW

View full text Add to dashboard Cite

The objective: to investigate serum heat shock protein 70 (HSP70) concentration in pregnant women with chronic hypertension and superimposed preeclampsia. To assess the prospects of using HSP70 as a superimposed preeclampsia predictor.Materials and methods. The original prospective cohort single-center observational study included 105 pregnant women with chronic hypertension and 34 healthy pregnant women as a control group. Serum HSP70 was measured via enzyme-linked immunosorbent assay. The first measurement point of serum HSP70 was at 28 weeks of gestation, the second measurement point was at 36 weeks in case of absence of preeclampsia or at 29-35 weeks in case of preeclampsia. If signs of preeclampsia appeared later than 36 weeks, additional HSP70 measurement was not performed. Statistical analysis was conducted using EZR 1.55 software.Results. In the study group (105 pregnant women with chronic hypertension), after delivery 30 patients had signs of superimposed preeclampsia (superimposed preeclampsia subgroup) and 75 persons had no signs of superimposed preeclampsia (chronic hypertension subgroup). In the control group (34 healthy pregnant women) 3 patients after delivery had preeclampsia signs (preeclampsia subgroup) and another 31 had no signs of preeclampsia (healthy subgroup).Serum HSP70 levels, obtained at the first measurement point (28 weeks) was statistically significantly different between three subgroups: patients with chronic hypertension vs. patients with superimposed preeclampsia (p<0.01), healthy pregnant women vs. chronic hypertension women (p<0.0001), healthy persons vs. superimposed preeclampsia persons (p<0.0001).Serum HSP70 concentrations at the second measurement point (36 weeks, or 29-35 weeks in case of preeclampsia) also had a statistically significant difference for each pair of subgroups (p<0.001). Given the small number of persons in the preeclampsia subgroup (3 women), it was not included in the calculations.No statistically significant difference between serum HSP70 levels in the first and second measurement points was found in healthy pregnant women subgroup. In the subgroup of pregnant women with chronic hypertension without superimposed preeclampsia complications, a statistically significant increased serum HSP70 concentration was found at 36 weeks compared to 28 weeks (p<0.0001). Even bigger growth of HSP70 levels compared to 28 weeks occurred in case of joining preeclampsia to chronic hypertension (p<0.0001).Conclusions. The data suggest an increased concentration of HSP70 in pregnant women with superimposed preeclampsia compared to pregnant women with chronic hypertension of the corresponding term. Thus, it is possible to assume that HSP70 plays a role in superimposed preeclampsia pathogenesis.The increased serum HSP70 levels in pregnant women with chronic hypertension, compared to healthy pregnant women of the corresponding gestational age was determined. Therefore, it can be argued that HSP70 has an influence on the course of chronic hypertension during pregnancy.No statistically significant dependance of serum HSP70 level in healthy pregnant women on gestational age was found. The increase in the level of HSP70 in pregnant women with chronic hypertension with increasing gestational age is most likely due to the progression of hypertensive disorders and/or related conditions. The highest HSP70 increase was observed in pregnant women with chronic hypertension with the addition of preeclampsia.The use of HSP70 as the only predictor of superimposed preeclampsia is not effective, given its non-specificity, but the use of this indicator in combination with other markers is promising and requires further study.

show abstract

“…Another study demonstrated that by vorinostat's inhibition of HDAC6, there was a boosted cardiac pump function and increased heat shock protein expression in MI rat models [206]. Heat shock proteins are responsible for protein maintenance and have arisen as a potential target for the treatment of CVD [207]. Vorinostat has also exhibited promise in the treatment of hypertension.…”

Section: Vorinostatmentioning

confidence: 99%

Traditional Therapeutics and Potential Epidrugs for CVD: Why Not Both?

Gladwell,

Ahiarah,

Rasheed

et al. 2023

Life

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the leading cause of death worldwide. In addition to the high mortality rate, people suffering from CVD often endure difficulties with physical activities and productivity that significantly affect their quality of life. The high prevalence of debilitating risk factors such as obesity, type 2 diabetes mellitus, smoking, hypertension, and hyperlipidemia only predicts a bleak future. Current traditional CVD interventions offer temporary respite; however, they compound the severe economic strain of health-related expenditures. Furthermore, these therapeutics can be prescribed indefinitely. Recent advances in the field of epigenetics have generated new treatment options by confronting CVD at an epigenetic level. This involves modulating gene expression by altering the organization of our genome rather than altering the DNA sequence itself. Epigenetic changes are heritable, reversible, and influenced by environmental factors such as medications. As CVD is physiologically and pathologically diverse in nature, epigenetic interventions can offer a ray of hope to replace or be combined with traditional therapeutics to provide the prospect of addressing more than just the symptoms of CVD. This review discusses various risk factors contributing to CVD, perspectives of current traditional medications in practice, and a focus on potential epigenetic therapeutics to be used as alternatives.

show abstract

The Role of Extracellular Heat Shock Proteins in Cardiovascular Diseases

Cited by 7 publications

References 110 publications

The Interplay between Heat Shock Proteins and Cancer Pathogenesis: A Novel Strategy for Cancer Therapeutics

The Interplay between Heat Shock Proteins and Cancer Pathogenesis: A Novel Strategy for Cancer Therapeutics

What is in common between preeclampsia, HPS70 and medieval headwear? Part II. Serum HSP70 in superimposed preeclampsia: original study

Traditional Therapeutics and Potential Epidrugs for CVD: Why Not Both?

Contact Info

Product

Resources

About